Stock Taper 
Corcept Therapeutics develops and commercializes drugs for severe metabolic, oncologic, and neuropsychiatric disorders, including Korlym for Cushing's syndrome and investigational treatments like relacorilant and nab-paclitaxel.
Korlym (mifepristone) is Corcept Therapeutics' flagship oral medication for treating hyperglycemia in adults with endogenous Cushing's syndrome and type 2 diabetes or glucose intolerance who are unsuitable for or have failed surgery.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Corcept Therapeutics' New Drug Application (NDA) for relacorilant in the treatment of hypercortisolism on December 31, 2025. The agency stated that it could not approve the application in its current form and requested additional evidence of the drug's effectiveness, a significant setback for a drug anticipated to be a major growth driver for the company.
In a major strategic move to diversify beyond its core hypercortisolism franchise, Corcept Therapeutics submitted a New Drug Application (NDA) to the FDA in July 2025 for its lead candidate, relacorilant, for the treatment of platinum-resistant ovarian cancer. This marks the company's most significant step to date into the oncology market, a new therapeutic area with substantial commercial potential.
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 42.7% of Xeris Biopharma
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Overall rating: B
| PEER | PRICE | |
|---|---|---|
 JAZZ | $230.95 | COMPARE |
 HALO | $110.55 | COMPARE |
 AXSM | $175.03 | COMPARE |
 CAI | $27.97 | COMPARE |
 CYTK | $61.19 | COMPARE |
 ABVX | $89.17 | COMPARE |
 RYTM | $90.29 | COMPARE |
 MBX | $51.93 | COMPARE |
